FDA-Drug2026-09-23Class ICHEMICAL
Vitruvias Therapeutics thyroid tablets recalled for superpotent drug
What this means
Vitruvias Therapeutics is recalling Thyroid Tablets, USP 1/2 Grain (30 mg) because the tablets are superpotent—meaning they contain higher-than-intended levels of active ingredients. This lot was distributed nationwide. The affected lot number is 504950, expiring 09/30/2026.
- Check if you have lot #504950 of Vitruvias Therapeutics Thyroid Tablets, USP 1/2 Grain.
- Contact your pharmacy or doctor immediately if you have this lot.
- Do not stop taking your thyroid medication without speaking to your doctor first.
- Your doctor will advise whether to switch to a different lot or brand.
The agency's original wording
Hazard
Superpotent Drug
Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide.
Affected count
1955 bottles
Manufactured in
778 N Dean Rd Ste 600, N/A, Auburn, AL, United States
Products
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0866-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.